A Comparison of Seroquel Vs. Risperidone in Schizophrenia - Tabular View

Tracking Information
First Received Date ^ICMJE	May 2, 2002
Last Updated Date	June 23, 2005
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00034905 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	A Comparison of Seroquel Vs. Risperidone in Schizophrenia
Official Title ^ICMJE
Brief Summary	The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.
Detailed Description
Study Phase	Phase IV
Study Type ^ICMJE	Interventional
Study Design ^ICMJE	Treatment
Condition ^ICMJE	Schizophrenia
Intervention ^ICMJE	Drug: quetiapine fumarate vs risperidone
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Completed
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria Male / Female, 18-65 years old Schizophrenia (as per DSM IV) Exclusion Criteria Concurrent use of psychotropic medication Does not fulfill moderately ill on CGI
Gender	Both
Ages	18 Years to 65 Years
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States

Administrative Information
NCT ID ^ICMJE	NCT00034905
Responsible Party
Study ID Numbers ^ICMJE	5077US/0043
Study Sponsor ^ICMJE	AstraZeneca
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	AstraZeneca
Verification Date	March 2003
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP